The Three Hours Saved That No One Would Buy

The successful automation demo on Tuesday, which cut three hours from our internal process, did not prove that an external customer actually valued the underlying problem enough to pay for a solution. While the automation was undeniably efficient for us, it revealed a common trap for founders: optimizing an internal pain point doesn't automatically translate to market demand for a product built around that optimization. We had built a better mousetrap, but the market wasn't looking for a better mousetrap, or at least not that mousetrap.

This situation brought to mind the early days of penicillin production in the 1940s. Sir Alexander Fleming had discovered penicillin in 1928, but it remained a laboratory curiosity for over a decade. The challenge wasn't proving penicillin's effectiveness, which was clear. The real problem was manufacturing it at scale. Researchers like Howard Florey and Ernst Chain at Oxford had shown its therapeutic potential, but producing enough for clinical trials, let alone widespread use, was an immense hurdle. The initial methods were slow, labor-intensive, and yielded tiny amounts. Imagine celebrating a small, hard-won batch of the drug, knowing it could save lives, but realizing the current production process could never meet the world's need. That was their Tuesday demo: a success in principle, but fundamentally unscalable for external demand. This initial production problem was eventually solved by a team at the USDA Northern Regional Research Laboratory in Peoria, Illinois, who, in 1941, discovered a more efficient strain of penicillin-producing mold and developed deep-tank fermentation methods, as detailed in The Mold in Dr. Florey's Coat by Eric Lax. Their innovation was not in finding a better medicine, but in making enough of it to matter.

The Illusion of Internal Validation

Our internal automation felt like a breakthrough because it solved a real, tangible problem for us. We documented the time savings, celebrated the reduced manual effort, and even calculated the potential cost savings if we scaled this specific process. What we overlooked, however, was the distinction between an internal operational improvement and a marketable product. The three hours we saved were valuable to our team, but they represented a very specific set of tasks within our operational context. The external market, we quickly learned, either didn't experience that exact pain point with the same intensity, or they had already found alternative, perhaps less elegant but sufficiently effective, workarounds. The cost of their current solution, or lack thereof, did not justify paying for our optimized alternative.

Why Time Savings Aren't Always Product Value

Saving time is often cited as a key benefit for any product. While true, whose time, what kind of time, and how much it's worth to them are critical questions. For our internal process, those three hours were a recurring headache for a high-value team member. For an external customer, that same three hours might be distributed across several lower-cost employees, absorbed by existing tools, or simply not seen as a critical bottleneck. The problem wasn't that our automation didn't save time. The problem was that the specific time saved did not map to a monetizable pain point in the market.

This is where the story of penicillin offers a parallel. The problem of curing bacterial infections was immense and universally recognized. Fleming, Florey, and Chain had proven penicillin was the solution. The internal problem they faced was production capacity. Solving that internal problem was essential to bringing the cure to the external market, but the market wasn't paying for "better fermentation methods." They were paying for "cured infections." Our automation, conversely, was closer to creating a slightly more efficient way to produce a small quantity of penicillin when the world was clamoring for a different, more pressing medical advancement entirely.

What We Missed: Problem Framing

Our mistake was framing the problem from an internal perspective. We focused on how we saved three hours, detailing the efficiency gains and the cleverness of the automation. What we should have done, much earlier, was to intensely validate the external problem itself:

• Is this specific problem widely felt by our target customers?
• How are they currently solving it?
• What is the actual, quantifiable cost (time, money, frustration) of their current solution?
• Does that cost justify a new product offering?

Without a clear external problem that resonates and is financially significant, even the most elegant internal solution remains just that: an internal solution. It's a useful tool for us, but not a product for them. We needed to step outside our operational bubble and engage deeply with potential users to understand their "jobs to be done" and what they would truly "hire" a product to achieve, rather than assuming our internal wins were universally applicable. This required a re-evaluation of our approach, pushing us to ask harder questions about true market needs, rather than celebrating our own cleverness.